Successful dupilumab treatment in a patient with severe dermatitis following allogenic hematopoietic stem cell transplantation.

IF 2.6 4区医学 Q2 ALLERGY

Allergy Asthma and Clinical Immunology Pub Date : 2025-04-29 DOI:10.1186/s13223-025-00966-3

Young-Hee Nam, Hyun Jung Jin

{"title":"Successful dupilumab treatment in a patient with severe dermatitis following allogenic hematopoietic stem cell transplantation.","authors":"Young-Hee Nam, Hyun Jung Jin","doi":"10.1186/s13223-025-00966-3","DOIUrl":null,"url":null,"abstract":"Background: Allogenic hematopoietic stem cell transplantation (HSCT) is the optimal treatment of hematologic diseases and various malignancies. Development of allergic disease in a transplant patient has been reported.Case presentations: A 49-year-old male with no history of atopy underwent two allogenic HSCTs for aplastic anemia from his brother with severe atopic dermatitis 11 years ago. The patient developed eczema on whole body and an elevated peripheral blood eosinophil count of 5775 cells/µL at 3 months after the second HSCT. Despite prolonged treatment with systemic corticosteroids and immunomodulators the skin rash and elevated blood eosinophil count persisted. However, after 4 months of dupilumab therapy, the patient showed near-complete clearance of symptoms. The sustained clinical improvement was observed during 36 months treatment without adverse drug reactions.Conclusions: Although rare, atopic dermatitis can occur after HSCT, and dupilumab may be safe and effective for refractory conditions.","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"18"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038993/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy Asthma and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13223-025-00966-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Allogenic hematopoietic stem cell transplantation (HSCT) is the optimal treatment of hematologic diseases and various malignancies. Development of allergic disease in a transplant patient has been reported.

Case presentations: A 49-year-old male with no history of atopy underwent two allogenic HSCTs for aplastic anemia from his brother with severe atopic dermatitis 11 years ago. The patient developed eczema on whole body and an elevated peripheral blood eosinophil count of 5775 cells/µL at 3 months after the second HSCT. Despite prolonged treatment with systemic corticosteroids and immunomodulators the skin rash and elevated blood eosinophil count persisted. However, after 4 months of dupilumab therapy, the patient showed near-complete clearance of symptoms. The sustained clinical improvement was observed during 36 months treatment without adverse drug reactions.

Conclusions: Although rare, atopic dermatitis can occur after HSCT, and dupilumab may be safe and effective for refractory conditions.

查看原文本刊更多论文

同种异体造血干细胞移植后严重皮炎患者dupilumab治疗成功。

背景：同种异体造血干细胞移植（HSCT）是治疗血液病和各种恶性肿瘤的最佳方法。曾有一例移植患者发生过敏性疾病的报道。病例介绍：一名49岁男性，无特应性病史，11年前因其患有严重特应性皮炎的兄弟再生障碍性贫血接受了两次同种异体造血干细胞移植。患者在第二次造血干细胞移植后3个月出现全身湿疹，外周血嗜酸性粒细胞计数升高至5775个细胞/µL。尽管长期使用全身皮质类固醇和免疫调节剂治疗，皮疹和血嗜酸性粒细胞计数升高持续存在。然而，在dupilumab治疗4个月后，患者显示症状几乎完全消除。治疗36个月，临床持续改善，无药物不良反应。结论：虽然罕见，但HSCT后可发生特应性皮炎，而dupilumab对于难治性疾病可能是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergy Asthma and Clinical Immunology ALLERGY-IMMUNOLOGY

CiteScore

4.30

自引率

3.70%

发文量

审稿时长

12 weeks

期刊介绍： Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease. By offering a high-visibility forum for new insights and discussions, AACI provides a platform for the dissemination of allergy and clinical immunology research and reviews amongst allergists, pulmonologists, immunologists and other physicians, healthcare workers, medical students and the public worldwide. AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.